HC Wainwright Cuts Immunic (NASDAQ:IMUX) Price Target to $5.00

Immunic (NASDAQ:IMUX) had its price objective lowered by HC Wainwright from $8.00 to $5.00 in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Immunic’s Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.63) EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at ($0.30) EPS, FY2029 earnings at ($0.20) EPS and FY2030 earnings at ($0.08) EPS.

Other research analysts have also issued reports about the stock. Brookline Capital Acquisition upgraded shares of Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a research note on Monday, December 29th. Chardan Capital raised Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. D. Boral Capital reduced their price objective on Immunic from $8.00 to $4.00 and set a “buy” rating for the company in a report on Friday, February 13th. Finally, Roth Mkm started coverage on Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $6.00.

Immunic Price Performance

Shares of IMUX stock opened at $1.17 on Monday. The business’s fifty day moving average price is $0.73 and its 200 day moving average price is $0.77. The firm has a market capitalization of $152.64 million, a PE ratio of -1.67 and a beta of 1.46. Immunic has a 1-year low of $0.51 and a 1-year high of $1.35.

Immunic (NASDAQ:IMUX) last issued its earnings results on Thursday, February 26th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Equities research analysts expect that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP purchased a new stake in Immunic in the fourth quarter valued at approximately $83,000. Connective Capital Management LLC acquired a new position in Immunic in the fourth quarter valued at $161,000. XTX Topco Ltd purchased a new stake in Immunic during the fourth quarter valued at about $120,000. Millennium Management LLC increased its stake in Immunic by 544.6% during the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock worth $1,825,000 after acquiring an additional 2,888,829 shares during the last quarter. Finally, Laurion Capital Management LP raised its holdings in shares of Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock worth $2,072,000 after purchasing an additional 2,000,000 shares during the period. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Key Immunic News

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: HC Wainwright raised several near‑term estimates — including Q3 2026 and Q4 2026 EPS and lifted FY2026 and FY2027 forecasts modestly (e.g., FY2026 from ($0.67) to ($0.63), FY2027 from ($0.53) to ($0.50)). These upward revisions and the continued “Buy” rating provide constructive analyst support for IMUX.
• Neutral Sentiment: Management will present at investor conferences in March (Leerink Partners Global Healthcare Conference and additional investor meetings). These events give investors fresh management access and potential clinical or program updates that could move the stock. Immunic to Participate in Investor Conferences in March
• Negative Sentiment: HC Wainwright lowered some near‑term quarter estimates — cutting Q1 2026 (to ($0.20) from ($0.15)) and trimming Q2 2026 (to ($0.17) from ($0.16)). Those downgrades signal continued cash‑burn/late‑stage biotech execution risk.
• Negative Sentiment: The firm also reduced multi‑year outlooks for FY2028 and FY2029 (e.g., FY2029 moved to ($0.20) from ($0.10)), indicating a dimmer mid‑term profit trajectory than previously modeled.
• Negative Sentiment: HC Wainwright lowered its price target to $5.00 (while retaining Buy), a downgrade in valuation terms that could cap upside until clearer clinical or commercial milestones are delivered. HC Wainwright Lowers Immunic (NASDAQ:IMUX) Price Target to $5.00

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.